# Is Precision Therapy in Infantile-Onset Epileptic Encephalopathieshes Still Too Far to Call Upon?
## 6 The Path Forward
Drugs with comparable side effect profiles may act through a shared mechanism, allowing them to be applied to the treatment of other diseases [36]. This knowledge is particularly important for countries with limited resources where 'old' drugs can be used for 'new' therapeutic targets, representing a variety of precision medicine. 3. Therapeutic Innovation: Expanding pipelines for gene-specific therapies is particularly impactful in pediatric care. For example, in the context of epileptic disorders, therapies targeting SCN1A mutations in Dravet Syndrome have shown transformative potential [37]. Precision treatments such as fenfluramine have demonstrated efficacy in significantly reducing seizure frequency and improving quality of life in affected children [38]. These innovations underscore the critical role of tailoring interventions to the genetic basis of pediatric epileptic conditions, fostering both better seizure management and enhanced developmental outcomes. 4. Global Collaboration: Enhancing data sharing and standardizing guidelines is vital in addressing rare pediatric epileptic disorders. For example, global initiatives like the International League Against Epilepsy's (ILAE) collaborative networks enable clinicians and researchers worldwide to pool genetic data, share clinical insights, and standardize treatment protocols [39]. This collective approach ensures that even children in resource-limited settings can benefit from the latest advancements in precision therapies, improving diagnostic and therapeutic outcomes across diverse healthcare systems. 5. Education and Advocacy: Empowering healthcare providers and patients through education is critical for the effective implementation of precision medicine [40]. For instance, in pediatric epilepsy, equipping clinicians with genomic knowledge allows them to recognize actionable mutations such as SCN1A in Dravet Syndrome, enabling timely and appropriate treatment adjustments. Additionally, educating families about genetic findings fosters informed decision-making and engagement in innovative therapies, ensuring the child receives optimal care. 6. Patient and Family Empowerment: Involving families in therapeutic decision-making and research is particularly impactful in pediatric epilepsy [41]. For instance, educating parents about the potential benefits of genetic testing can lead to earlier identification of mutations such as SCN1A, allowing them to advocate for targeted therapies like fenfluramine for Dravet Syndrome. Additionally, involving families in clinical trials fosters a deeper understanding of available treatments and enhances engagement in the child's care plan, ultimately improving outcomes and quality of life. 7. Strategies to increase affordability and improve equitable access: To increase the affordability and improve equitable access to precision medicine and therapy, global collaborations could play a pivotal role. By fostering partnerships between governments, healthcare providers, pharmaceutical companies, and research institutions, the cost burden of developing and implementing precision therapies can be shared. Such collaborations could enable pooled resources for research and development, making therapies more affordable and widely accessible, particularly in low- and middle-income countries. Through shared knowledge, economies of scale, and harmonized policies, these global efforts could address disparities in access, ensuring that the benefits of precision medicine reach diverse populations around the world.